BioNTech is about to cross a threshold it has never reached before. The Mainz-based biotech is preparing its inaugural application to the US Food and Drug Administration for a cancer drug — a regulatory milestone that, in a normal world, would spark a rally. Instead, the shares are nursing a 20% plunge triggered by the announcement that founders Ugur Sahin and Özlem Türeci will depart at the end of 2026 to launch a new mRNA venture.
The contrast between clinical progress and market sentiment has rarely been starker. At €80.00, the stock sits roughly 24% below its January high and 25% under its 52-week peak of €105.80. The 14-day relative strength index of 54.4 suggests no momentum extreme — the equity is simply drifting while one of the industry’s densest oncology pipelines runs at full speed beneath the surface.
The historic filing and the data behind it
BioNTech, together with Chinese partner DualityBio, intends to submit Trastuzumab Pamirtecan for approval in advanced endometrial cancer. The antibody-drug conjugate already enjoys FDA fast-track designation. The filing rests on a Phase 2 study of 145 patients that delivered an overall response rate of nearly 48%, climbing to 73% in patients with the highest HER2 expression.
The drug’s potential edge over AstraZeneca’s blockbuster Enhertu is that it appears to work across all levels of HER2 expression, not only the top tier. A global confirmatory study is already underway, and Chinese regulators have been reviewing the same data since April. The US submission would mark the first time BioNTech has brought a wholly oncology asset before the FDA — a moment the company’s science-driven leadership has spent a decade preparing for.
Yet the euphoria that might accompany that step is being smothered by the founder exit. The supervisory board has not named successors, leaving a scientific and strategic vacuum at the very moment the pipeline demands flawless execution.
A pipeline that rewards patience — or punishes it
Trastuzumab Pamirtecan is only one piece of a much larger mosaic. BioNTech plans to launch six additional Phase 3 oncology studies this year, bringing its total number of late-stage trials to 15. Seven major data readouts are expected in the second half of 2026 alone. Among the most anticipated: Phase 3 results for Gotistobart in non-small cell lung cancer, Phase 3 data for the mRNA candidate BNT113 in head and neck cancer, and the aforementioned Trastuzumab Pamirtecan filing.
The breadth is extraordinary for a company still largely perceived as a vaccine play. More than 25 Phase 2 and Phase 3 studies are running concurrently, 13 of them potentially pivotal. The sheer number of binary decision points means the probability of total disappointment is low — but the margin for error is tiny when management is about to turn over.
Should investors sell immediately? Or is it worth buying BioNTech?
At the ASCO congress in Chicago earlier this year, the company presented encouraging data: Pumitamig showed a 70% response rate in a Phase 2 trial for first-line non-small cell lung cancer (covering both squamous and non-squamous subtypes), and Gotistobart delivered durable tumor activity and clinically meaningful survival in heavily pre-treated platinum-resistant ovarian cancer patients. These results were confirmatory, not transformative. They validated the direction of travel without providing the catalyst the stock needed.
A balance sheet that buys time
BioNTech’s market capitalisation of roughly €20 billion, measured against its substantial cash position, effectively prices the entire oncology pipeline at just a few billion euros. The analyst consensus target of €106.55 implies more than 33% upside — a gap that reflects a structural disagreement between what the pipeline is worth and what investors are currently willing to pay.
That valuation discount is not irrational on its face. The company guided for significantly lower revenue in 2026 versus 2025, and research and selling costs are climbing. In the first quarter of 2026, BioNTech reported a net loss on revenue of just €118 million, with research spending alone reaching €557 million. No oncology product revenue will flow this year. Competition in lung cancer is intensifying: BioNTech and Bristol-Myers Squibb expanded the ROSETTA-Lung-02 trial to 1,260 patients to ensure statistical power, while Pfizer is sticking with overall survival as a dual primary endpoint in a rival study.
Those are genuine risks. Yet the bear thesis ultimately requires that the entire pipeline produce no value — an assumption that grows harder to sustain with each positive data point. Citi recently described BioNTech as a “differentiated player among traditional vaccine names” that is “continuing its transformation into a commercial oncology company.”
The buyback, the floor, and the second half
The stock has eked out a 5% gain over the past 30 days, suggesting some investors are positioning ahead of the upcoming data waves. The March low of €68.35 — roughly 17% below current levels — increasingly looks like a durable floor. A balance sheet that makes capital raises unnecessary gives the company a luxury most biotech peers lack, and management’s own conviction is underscored by a $1 billion share buyback program running until May 2027.
But the founder overhang will not dissipate until the supervisory board names replacements. For a company as scientific as BioNTech, a leadership transition of this magnitude injects execution risk at precisely the wrong moment. The second half of 2026 is therefore a test on two fronts: the data must prove that billions in R&D investment are paying off, and the board must prove it can steer the ship without its architects. Solve both, and the current valuation looks like an invitation. Fail on either, and the drift may deepen.
Ad
BioNTech Stock: Buy or Sell?! New BioNTech Analysis from June 18 delivers the answer:
The latest BioNTech figures speak for themselves: Urgent action needed for BioNTech investors. Is it worth buying or should you sell? Find out what to do now in the current free analysis from June 18.
BioNTech: Buy or sell? Read more here...
